Drug Discovery


Logo for TruAB

Developing Therapeutic Antibodies Against SARS-CoV-2

Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to SARS-CoV-2.

Diagram showing the flow of Data.

Adaptive has identified and characterized ultra-potent, neutralizing antibodies to SARS-CoV-2. Our antibodies can be considered for development as either differentiated monoclonal antibodies or as synergistic antibody cocktail to treat or prevent COVID-19.

Beyond COVID-19, Adaptive is exploring applications of TruAB discovery in other diseases, including autoimmunity.